Silexion Therapeutics shares fall after wider Q1 loss and lower cash balance despite pancreatic cancer trial progress.
Stock Earnings Results
May 18, 2026
Table of Contents
May 18, 2026
Silexion Therapeutics Corp. (NASDAQ: SLXN) reported first-quarter 2026 results with a wider net loss and lower cash balance, while highlighting regulatory progress for its planned Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.
Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.
The company’s listed earnings event showed a 22.58% current decline, with shares trading at $0.012 in premarket activity.
Silexion said its Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026.
The company received approval from the Israeli Ministry of Health on March 24, 2026, to begin its Phase 2/3 trial evaluating SIL204 for locally advanced pancreatic cancer. Silexion also submitted a Clinical Trial Application to Germany through the EU Clinical Trials Information System after quarter-end.
SIL204 is designed to silence mutated KRAS, a driver present in about 90% of pancreatic cancers.
The planned trial is expected to begin with an initial safety run-in cohort of about 18 patients, followed by a randomized cohort of about 166 patients. The study will evaluate SIL204 with standard chemotherapy using intratumoral and systemic administration.
Research and development expenses rose to about $1.4 million in Q1 2026 from about $0.6 million in the prior-year period.
The increase was mainly tied to toxicology studies, product development, GMP manufacturing, and preparation for the planned human clinical trial.
Silexion reported a net loss of about $2.7 million, compared with a net loss of about $1.7 million in Q1 2025.
The wider loss reflected higher R&D spending and higher general and administrative expenses tied to public company costs and clinical readiness.
Cash and cash equivalents fell to $2.4 million as of March 31, 2026, down from $6.0 million at the end of 2025.
After quarter-end, Silexion raised about $1.0 million through a warrant exercise inducement transaction and used its at-the-market facility. The company said these actions helped restore shareholder equity above the Nasdaq Capital Market’s $2.5 million continued listing requirement.
Investors are likely to watch whether Silexion can begin its Phase 2/3 trial on schedule while maintaining enough capital to fund development.
The key areas are:
Silexion’s update showed clinical progress, but the stock reaction suggests investors focused on cash burn, financing needs, and execution risk.
The company is moving toward human clinical development for SIL204, but its cash position remains limited. The next major catalyst is whether the Phase 2/3 trial begins on schedule and whether Silexion can fund development without heavy dilution.
Platforms like LevelFields track earnings misses, layoffs, dividend increases, leadership changes, and medical technology stock reactions together, helping investors identify when small-cap healthcare stocks are moving on balance sheet progress rather than current revenue alone.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE